References

[1] King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21: 1414-31.

[2] Centers for Disease Control. National Health and Nutrition Examination Survey 1999-2000 data files. Available at: http://www.cdc.gov/nchs/about/major/ nhanes/NHANES99_00.htm. Accessed December 21, 2004.

[3] International Diabetes Federation. IGT/IFG Consensus. Statement Report of an expert consensus workshop, August 1-4, 2001. Stoke Poges, United Kingdom. Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention. Diabet Med 2002;19:708-23.

[4] Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002;156: 714-9.

[5] Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281:1291-7.

[6] Ruige JB, Assendelft WJ, Dekker JM, et al. Insulin and risk of CV disease: a meta-analysis. Circulation 1998;97(10):996-1001.

[7] Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998;83:2773-6.

[8] Facchini FS, Hua N, Abbasi F, et al. Insulin resistance as a predictor of age related diseases. J Clin Endocrinol Metab 2001;86:3574-8.

[9] Fagan TC, Deedwania PC. The cardiovascular dys-metabolic syndrome. Am J Med 1998;105(1A): 77S-82S.

[10] Abbasi F, McLaughlin T, Lamendola C, et al. The relationship between glucose disposal in response to physiological hyperinsulinemia and basal glucose and free fatty acid concentrations in healthy volunteers. J Clin Endocrinol Metab 2000;85: 1252-4.

[11] Taskinen MR, Smith U. Lipid disorders in NIDDM: implications for treatment. J Intern Med 1998;244: 361-70.

[12] Garg A. Treatment of diabetic dyslipidemia. Am J Cardiol 1998;81:47B-51B.

[13] Veniant MM, Sullivan MA, Kim SK, et al. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest 2000; 106:1501-10.

[14] Stamler J, Vaccaro I, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16: 434-44.

[15] Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316: 823-8.

[16] Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990;13:153-69.

[17] Pyorola K, Pederson TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a sub-group analysis of the Scandinavian Simvasta-tin Survival Study (4S). Diabetes Care 1997;20: 614-20.

[18] Goldberg RB, Mellies MJ, Sacks FM, et al, for the CARE investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose- intolerant myocardial infarction survivors with average cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-9.

[19] Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with sim-vastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361(9374): 2005-16.

[20] Colhoun HM, Betteridge DJ, Durrington PN, et al, for the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 2004;364(9435): 685-96.

[21] Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high- density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.

[22] Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

[23] Grundy SM, Cleeman JI, Bairey Merz CN, et al, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.

[24] Ferrannini E, Buzzigoli G, Bonadona R. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7.

[25] Swislocki ALM, Hoffman BB, Raven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2:419-23.

[26] United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications of type 2 diabetes: UKPDS 38. BMJ 1998;317: 703-13.

[27] Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351: 1755-62.

[28] Wright JT Jr, Jones DW, Green LA, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-71.

[29] Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36(3):646-61.

[30] Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy. Lancet 2000;355: 253-9 [published correction appears in Lancet 2000;356:850].

[31] Kidney Disease Outcome Quality Initiative. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.

[32] Poulter N, Williams B. Doxazosin for the management of hypertension: implications of the findings of the ALLHAT Trial. Am J Hypertens 2001;14: 1170-2.

[33] United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulpho-nylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.

[34] United Kingdom Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

[35] Khaw KT, Wareham N, Luben R, et al. Glycated hemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322(7277):15-8.

[36] European Diabetes Epidemiology (DECODE) Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26(3):688-96.

[37] Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2002;357:89-95.

[38] Colwell JA. Aspirin therapy in diabetes. Diabetes Care 2003;26(Suppl 1):S87-8.

[39] United States Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med 2001;136:157-60.

[40] Antithrombotic Trialists' Collaboration. Collaboration meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.

[41] Bhatt D, Marso S, Hirsh A, Ringleb P, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90: 625-8.

[42] Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348: 383-93.

[43] Hoerger TJ, Bethke AD, Richter A, et al. The CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287:2542-51.

[44] Saydah S, Fradkin J, Cowie C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291: 335-42.

[45] Clark CM, Fradkin JE, Hiss RG, et al. The National Diabetes Education Program, changing the way diabetes is treated. Diabetes Care 2001;24:617-8.

[46] Fleming BB, Greenfield S, Engelgau MM, et al. The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. Diabetes Care 2001;24:1815-20.

[47] American Diabetes Association. Standards of Medical Care in Diabetes—position statements. Diabetes Care 2004;27:S15-35.

[48] Lindstrom J, Eriksson JG, Valle TT, et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish diabetes prevention study: results from a randomized clinical trial. J Am Soc Nephrol 2003;14(7 Suppl 2):S108-13.

[49] The DPP Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346: 393-403.

[50] Chiasson JL, Josse RG, Gomis R, et al, for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359: 2072-7.

[51] Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The seventh report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). JAMA 2003;289(19): 2560-72.

[52] Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report published by the National Institutes of Health, National Heart, Lung, and Blood Institute in June 1998.

[53] Lauber RP, Sheard NF. The American Heart Association dietary guidelines for 2000: a summary report. Nutr Rev 2001;59(9):298-306.

[54] Sobel BE, Schneider DJ. Platelet function, coagu-lopathy and impaired fibrinolysis in diabetes. Cardiol Clin 2004;22(4):511-26.

ELSEVIER SAUNDERS

Cardiol Clin 23 (2005) 211-220

CARDIOLOGY CLINICS

Keep Your Weight In Check During The Holidays

Keep Your Weight In Check During The Holidays

A time for giving and receiving, getting closer with the ones we love and marking the end of another year and all the eating also. We eat because the food is yummy and plentiful but we don't usually count calories at this time of year. This book will help you do just this.

Get My Free Ebook


Post a comment